Tirzepatide Brand Name: Mounjaro, Zepbound, Yurpeak

Summary: Tirzepatide is sold as Mounjaro and Zepbound in the US, as Mounjaro or Yurpeak in India, and as Zepbound in Japan. What each label actually covers.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Tirzepatide is sold in the United States under exactly two brand names: Mounjaro and Zepbound. Both are made by Eli Lilly, both contain the same molecule, and both come in the same six strengths. What separates them is the label: Mounjaro is the type 2 diabetes brand, Zepbound is the obesity and sleep apnea brand.

Search the Drugs@FDA database for every approved product whose active ingredient is tirzepatide and you get two applications and nothing else, both held by Eli Lilly: NDA 215866 (Mounjaro) and NDA 217806 (Zepbound). There is no third US brand, no authorised generic, and no abbreviated application from another manufacturer.

Outside the US the picture changes. Europe has only Mounjaro. Japan has both Mounjaro and Zepbound. India has Mounjaro plus a second brand, Yurpeak, sold by Cipla under an agreement with Lilly.

Why one molecule carries two brand names

Mounjaro was approved first, on 13 May 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It was classified by FDA as a Type 1 new molecular entity, meaning tirzepatide had never been approved in any product before.

Rather than adding weight management to the Mounjaro label, Lilly filed a separate application. Zepbound was approved on 8 November 2023, and Drugs@FDA classifies that submission as a new indication submitted as a distinct NDA. That is the whole reason two brand names exist for one molecule, and it is why both prescribing information documents still say "Initial U.S. Approval: 2022" at the top. The clock belongs to the molecule, not the brand.

The practical consequence shows up at the pharmacy counter. A benefit plan that covers diabetes drugs but excludes obesity drugs can pay for one carton and refuse the identical one next to it, because the brand name on the box is what the claim is adjudicated against. If you are comparing the two on paper, our side-by-side on Mounjaro vs Zepbound breaks down where the labels diverge, and what is Mounjaro covers the diabetes brand on its own terms.

What the Mounjaro label covers

The current US Mounjaro prescribing information, revised April 2026, indicates it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. That pediatric extension is recent. Earlier versions of the label, including the September 2025 revision, said safety and effectiveness had not been established in pediatric patients at all.

On 28 August 2026, Lilly announced that FDA had approved a further Mounjaro indication: to lower the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are at high risk for these events. The approval rests on SURPASS-CVOT, which randomised 13,299 participants across 640 sites in 30 countries and compared tirzepatide against dulaglutide, an older Lilly GLP-1 with an established cardiovascular benefit. Lilly reports an 8% lower rate of the three-part MACE endpoint, hazard ratio 0.92 (95.3% CI 0.83 to 1.01). Because dulaglutide is the comparator rather than placebo, our Mounjaro vs Trulicity page is the relevant background.

Worth flagging honestly: that cardiovascular wording had not yet appeared in the posted DailyMed label when this article was written. The label text quoted above is the April 2026 revision.

What the Zepbound label covers

Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity:

• to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition
• to treat moderate to severe obstructive sleep apnea in adults with obesity

The original approval letter sets the entry criteria as a body mass index of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The sleep apnea indication was added on 20 December 2024 and was the first time FDA approved any medication for obstructive sleep apnea.

The Zepbound label also carries a Limitations of Use statement that answers a question people ask constantly: coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended. Stacking Mounjaro and Zepbound is not a way to get more drug. It is the same molecule twice.

Tirzepatide brand names outside the United States

European Union and United Kingdom. Mounjaro is the only tirzepatide brand. The EMA authorised it on 15 September 2022 to Eli Lilly Nederland B.V., and the European label covers both jobs: type 2 diabetes in adults and children aged 10 and over, and weight management in adults with a BMI of 30 or more, or 27 to 30 with weight-related comorbidities. Zepbound is not an EU product. Someone in Manchester taking Mounjaro for weight loss is not doing anything off-label there, even though the same use would carry the Zepbound name in the US.

Japan. Both brands exist. Zepbound subcutaneous injection, supplied in the single-use Ateos autoinjector, was listed on the National Health Insurance price list on 19 March 2025 and released on 11 April 2025, marketed by Eli Lilly Japan with Mitsubishi Tanabe Pharma. Its approved indication is "obesity disease" limited to people with hypertension, dyslipidemia, or type 2 diabetes who have not responded adequately to diet or exercise, and who have either a BMI of 27 or higher with at least two obesity-related conditions, or a BMI of 35 or higher.

India. Mounjaro came first. In October 2025, Lilly and Cipla announced an agreement under which Lilly manufactures and supplies tirzepatide and Cipla distributes and promotes it as Yurpeak, in the multi-dose KwikPen presentation, at the same price as Mounjaro. Cipla announced the Yurpeak launch in December 2025. Yurpeak is the same tirzepatide with a different label on the carton, which is a co-marketing arrangement rather than a generic.

KwikPen, autoinjector and Ateos are device names, not drug brands

Drugs@FDA lists Mounjaro under three product names, and Zepbound under the same three: the base name, "(AUTOINJECTOR)", and "KWIKPEN". These are presentations, not distinct medicines.

The single-dose pen and single-dose vial hold 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL. The KwikPen is a single-patient-use multi-dose pen containing four doses, which is why its listed strengths read as 10 mg to 60 mg per 2.4 mL. Japan's Ateos is another autoinjector housing. None of this changes the drug inside. If you want the pharmacology rather than the packaging, see how tirzepatide works.

Which strength anyone uses, and how it changes over time, is a prescriber's decision made against the label's escalation schedule, not something to copy from an article.

Is there a generic tirzepatide?

No. As of this writing, Drugs@FDA holds no abbreviated new drug application for tirzepatide from any company. Every FDA-approved tirzepatide product traces back to one of Lilly's two NDAs. Products advertised online as "generic tirzepatide", "tirzepatide research peptide", or a low-cost tirzepatide brand you have never heard of are not FDA-approved generics, whatever the listing says. Cost pressure is real, and our tirzepatide cost page covers what the branded products actually run, but the pricing problem does not create a legal generic that does not exist.

Compounded tirzepatide is not a brand name

During the 2022 to 2024 shortage, compounding pharmacies were permitted to make tirzepatide copies. FDA issued a declaratory order on 19 December 2024 confirming the shortage was resolved, and set wind-down windows: state-licensed 503A pharmacies until 18 February 2025, and 503B outsourcing facilities until 19 March 2025. After those dates, compounded copies of tirzepatide lost their enforcement cover.

Compounded preparations are not FDA-approved products and are not reviewed for safety, effectiveness, or manufacturing quality before they reach patients. A telehealth brand name printed on a compounded vial is a company's marketing name, not a drug brand in the regulatory sense. Compounded vs regular tirzepatide goes through the distinction in more detail.

Frequently asked questions

Are Mounjaro and Zepbound the same drug? Same active ingredient, same manufacturer, same strengths, different approved indications and different labels. They are not interchangeable at the pharmacy, and the labels advise against taking them together.

Is tirzepatide the brand name or the generic name? Tirzepatide is the nonproprietary name of the molecule, the same way semaglutide is. It is not a "generic" in the sense of a competing manufacturer's copy, because no such copy is approved.

What is tirzepatide called in the UK? Mounjaro. There is no Zepbound in the UK or the wider EU market; the single Mounjaro authorisation covers both diabetes and weight management there.

Why did my prescription switch from Mounjaro to Zepbound? Usually because the prescribing reason or the coverage pathway changed rather than the medicine. Only a prescriber and your plan can confirm what happened on a specific prescription.

Is there a tablet version of tirzepatide? Not among approved products. Every tirzepatide brand described here is a once-weekly subcutaneous injection. Oral GLP-1 medicines exist, but they are different molecules, not tirzepatide in pill form.

This article describes what regulatory labels and manufacturer announcements report. It is not medical advice, and it does not tell anyone what to take or at what dose. Talk to a prescriber.